Hypoxia-Inducible Factor 1A Upregulates HMGN5 by Increasing the Expression of GATA1 and Plays a Role in Osteosarcoma Metastasis

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Jan 14

PMID 31930127

Citations 6

Authors

Enjie Xu

Zhe Ji

Heng Jiang

Tao Lin

Jun Ma

Xuhui Zhou

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma is one of the most common malignant tumors in children and adolescents and is characterized by early metastasis. High-mobility group N (HMGN) domains are involved in the development of several tumors. Our previous study found that HMGN5 is highly expressed in osteosarcoma tissues and knockdown of HMGN5 inhibits migration and invasion of U-2 OS and Saos-2 cells. A hypoxic environment is commonly found in solid tumors such as osteosarcoma and is likely to be associated with tumor metastasis, so we further explored the relationship between HMGN5 and the hypoxic environment. Hypoxia-inducible factor 1A (HIF1A) is an adaptive factor in the hypoxic environment. We found that HIF1A and HMGN5 were upregulated in osteosarcoma (OS) cells cultured in the hypoxic environment, and the results of overexpression and knockdown experiments showed that HIF1A upregulated the transcription factor GATA1 and further promoted the expression of HMGN5. In addition, MMP2 and MMP9 were subsequently upregulated through the c-jun pathway, and finally, this promoted the migration and invasion of OS cells. It is suggested that HMGN5 may be an important downstream factor for HIF1A to promote osteosarcoma metastasis. It has an important clinical significance for the selection of therapeutic targets for osteosarcoma.

Citing Articles

KCNJ2/HIF1α positive-feedback loop promotes the metastasis of osteosarcoma.

Shen M, Pan R, Lei S, Zhang L, Zhou C, Zeng Z Cell Commun Signal. 2023; 21(1):46.

PMID: 36864422 PMC: 9979522. DOI: 10.1186/s12964-023-01064-w.

Testis-expressed gene 11 inhibits cisplatin-induced DNA damage and contributes to chemoresistance in testicular germ cell tumor.

Kitayama S, Ikeda K, Sato W, Takeshita H, Kawakami S, Inoue S Sci Rep. 2022; 12(1):18423.

PMID: 36319719 PMC: 9626550. DOI: 10.1038/s41598-022-21856-3.

The Key Network of mRNAs and miRNAs Regulated by HIF1A in Hypoxic Hepatocellular Carcinoma Cells.

Liu T, Tang J, Li X, Lin Y, Yang Y, Ma K Front Genet. 2022; 13:857507.

PMID: 35774500 PMC: 9237512. DOI: 10.3389/fgene.2022.857507.

High Mobility Group Proteins in Sepsis.

Liang G, He Z Front Immunol. 2022; 13:911152.

PMID: 35720285 PMC: 9202578. DOI: 10.3389/fimmu.2022.911152.

1,25(OH) D blocks IFNβ production through regulating STING in epithelial layer of oral lichen planus.

Ge X, Wang Y, Xie H, Li R, Zhang F, Zhao B J Cell Mol Med. 2022; 26(13):3751-3759.

PMID: 35644988 PMC: 9258715. DOI: 10.1111/jcmm.17409.

References

Xu E, Lin T, Jiang H, Ji Z, Shao W, Meng Y . Asymmetric expression of GPR126 in the convex/concave side of the spine is associated with spinal skeletal malformation in adolescent idiopathic scoliosis population. Eur Spine J. 2019; 28(9):1977-1986. DOI: 10.1007/s00586-019-06001-5. View

Botter S, Neri D, Fuchs B . Recent advances in osteosarcoma. Curr Opin Pharmacol. 2014; 16:15-23. DOI: 10.1016/j.coph.2014.02.002. View

Gan Y, Tan J, Yang J, Zhou Y, Dai Y, He L . Knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5637 cells in vitro and in vivo. Med Oncol. 2015; 32(4):136. DOI: 10.1007/s12032-015-0594-y. View

Yang Q, Zeng B, Dong Y, Shi Z, Jiang Z, Huang J . Overexpression of hypoxia-inducible factor-1alpha in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol. 2007; 37(2):127-34. DOI: 10.1093/jjco/hyl137. View

Fuchs N, Bielack S, Epler D, Bieling P, Delling G, Korholz D . Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998; 9(8):893-9. DOI: 10.1023/a:1008391103132. View

Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A . Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993; 72(11):3227-38. DOI: 10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c. View

Wittig J, Bickels J, Priebat D, Jelinek J, Shmookler B, Malawer M . Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002; 65(6):1123-32. View

Yang J, Zhang W . New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013; 25(4):398-406. DOI: 10.1097/CCO.0b013e3283622c1b. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

10.

Wu J, Wang J . HMGN5 expression in bladder cancer tissue and its role on prognosis. Eur Rev Med Pharmacol Sci. 2018; 22(4):970-975. DOI: 10.26355/eurrev_201802_14378. View

11.

Wagner M, Livingston J, Patel S, Benjamin R . Chemotherapy for Bone Sarcoma in Adults. J Oncol Pract. 2016; 12(3):208-16. DOI: 10.1200/JOP.2015.009944. View

12.

Jo V, Fletcher C . WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014; 46(2):95-104. DOI: 10.1097/PAT.0000000000000050. View

13.

Provisor A, Ettinger L, Nachman J, Krailo M, Makley J, Yunis E . Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15(1):76-84. DOI: 10.1200/JCO.1997.15.1.76. View

14.

Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi J, Gaub M . Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer. 2014; 13:58. PMC: 3975457. DOI: 10.1186/1476-4598-13-58. View

15.

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G . Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006; 32(6):423-36. DOI: 10.1016/j.ctrv.2006.05.005. View

16.

Garcia P, Berlanga O, Vegiopoulos A, Vyas P, Frampton J . c-Myb and GATA-1 alternate dominant roles during megakaryocyte differentiation. J Thromb Haemost. 2011; 9(8):1572-81. DOI: 10.1111/j.1538-7836.2011.04396.x. View

17.

Fagerberg L, Hallstrom B, Oksvold P, Kampf C, Djureinovic D, Odeberg J . Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2013; 13(2):397-406. PMC: 3916642. DOI: 10.1074/mcp.M113.035600. View

18.

Palmerini E, Jones R, Marchesi E, Paioli A, Cesari M, Longhi A . Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer. 2016; 16:280. PMC: 4839113. DOI: 10.1186/s12885-016-2312-3. View

19.

Nakano K, Takahashi S . Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. Int J Mol Sci. 2018; 19(3). PMC: 5877600. DOI: 10.3390/ijms19030739. View

20.

Ji S, Yao L, Zhang X, Li X, Zhou L . Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo. J Exp Clin Cancer Res. 2012; 31:22. PMC: 3325891. DOI: 10.1186/1756-9966-31-22. View